Allergan PLC. (NYSE:AGN)‘s stock had its “hold” rating reissued by research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday.

A number of other analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research report on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) lowered shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a research report on Wednesday, May 10th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Royal Bank Of Canada raised their target price on shares of Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research report on Wednesday, May 10th. Finally, Deutsche Bank AG restated a “buy” rating and issued a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $275.49.

Allergan PLC. (NYSE:AGN) traded down 0.24% during mid-day trading on Tuesday, reaching $223.40. The company had a trading volume of 597,299 shares. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The stock has a market capitalization of $74.68 billion, a price-to-earnings ratio of 6.81 and a beta of 1.16. The company’s 50 day moving average is $240.49 and its 200 day moving average is $238.48.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter last year, the business posted $3.35 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. Equities analysts predict that Allergan PLC. will post $16.27 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Allergan PLC.’s (AGN) Hold Rating Reiterated at Cantor Fitzgerald” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/allergan-plc-s-agn-hold-rating-reiterated-at-cantor-fitzgerald/1530131.html.

A number of large investors have recently bought and sold shares of AGN. Howard Hughes Medical Institute bought a new stake in Allergan PLC. during the second quarter worth approximately $103,000. Enterprise Financial Services Corp boosted its stake in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares during the last quarter. Jacobi Capital Management LLC boosted its stake in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the last quarter. JNBA Financial Advisors boosted its stake in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the last quarter. Finally, Massey Quick & Co. LLC boosted its stake in Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after buying an additional 385 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.